On April 2, 2025, the Alliance for mRNA Medicines held several Hill meetings to discuss the promise of mRNA medicines and therapeutics for treating cancer and rare diseases, the threat posed to mRNA by recent actions and funding cuts, and initial data gathered by AMM on the consequences this poses for jobs, patients, innovation, and U.S. competitiveness.
